Mar. 18 at 8:19 PM
$DNTH
Dianthus Therapeutics, Inc. reported a loss of
$1.43 per share for Q4 2025, wider than the expected loss of
$1.03 per share.
The biotech posted a net loss of
$64.4 million for the quarter.
The wider-than-expected loss marks a significant deterioration from the prior quarter’s
$0.97 per share loss and
$0.81 per share loss reported in Q4 2024.
Revenue collapses year-over-year. The company generated just
$280,000 in revenue for the quarter, down 78.9% from
$1.3 million in the year-ago period.
Sequentially, revenue declined from Q3 2025’s
$396,000.
The minimal revenue base reflects the company’s early-stage development profile, with the business still heavily dependent on research milestones rather than commercial product sales.
Despite the operational losses, shares surged 21.5% on volume of 4.6 million shares, suggesting investors are focused on pipeline developments rather than near-term profitability.
